 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Tumor infiltrating B cells can predict the clinical prognosis of melanoma patients treated with dabrafenib + trametinib

Clin Cancer Res: Tumor infiltrating B cells can predict the clinical prognosis of melanoma patients treated with dabrafenib + trametinib

 Last Update: 2021-08-26
 Source: Internet
 Author: User

Tags

what all cells

placental cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Although patients with unresectable or metastatic melanoma using BRAF and MEK targeted drugs or immune checkpoint inhibitors can treat long-term survival of more than 5 years, most patients will develop drug resistance

immunity

Researchers such as Brase used gene expression profiling and digital pathology to perform a predetermined exploratory biomarker analysis of 146 previously untreated patients with metastatic melanoma carrying BRAF v600 mutations.

PFS and OS of patients grouped according to B cell genetic characteristics

Baseline cell cycle gene expression characteristics are correlated with progression-free survival (p=0.

Baseline cell cycle gene expression characteristics are correlated with progression-free survival.

PFS and OS in patients grouped according to the level of T cell and B cell infiltration

In summary, B cells can be used as potential biomarkers to predict the clinical prognosis of patients with advanced melanoma treated with dabrafenib combined with trametinib

B cells can be used as potential biomarkers to predict the clinical prognosis of patients with advanced melanoma treated with dabrafenib combined with trametinib.

Original source:

Jan C.

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Wholesale Cheap Price Bulk Price Aclarubicin CAS 57576-44-0

CAS No.: 57576-44-0

$1/UNIT FOB

Vandetanib

CAS No.: 443913-73-3

Different Grade

$0.1/KG EXW

Camptothecin CAS 7689-03-4

CAS No.: 7689-03-4

Pharmacy Grade

$38-45/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.